Symbols / EYPT Stock $13.66 +1.86% EyePoint, Inc.

Healthcare • Biotechnology • United States • NGM
EYPT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jay S. Duker M.D.
Exch · Country NGM · United States
Market Cap 1.15B
Enterprise Value 1.27B
Income -271.60M
Sales 7.61M
FCF (ttm) —
Book/sh 0.40
Cash/sh 0.48
Employees 214
Insider 10d —
IPO Jan 27, 2005
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.92
PEG —
P/S 150.42
P/B 34.49
P/C —
EV/EBITDA -4.54
EV/Sales 166.71
Quick Ratio 5.97
Current Ratio 6.66
Debt/Eq 46.82
LT Debt/Eq —
EPS (ttm) -3.51
EPS next Y -2.78
EPS Growth —
Revenue Growth 161.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-06
ROA -54.13%
ROE -102.71%
ROIC —
Gross Margin 0.00%
Oper. Margin -4.51%
Profit Margin 0.00%
Shs Outstand 83.84M
Shs Float 65.73M
Insider Own 3.67%
Instit Own 106.30%
Short Float 18.97%
Short Ratio 14.69
Short Interest 13.66M
52W High 19.11
vs 52W High -28.52%
52W Low 5.30
vs 52W Low 157.74%
Beta 1.77
Impl. Vol. 1.05%
Rel Volume 0.52
Avg Volume 1.28M
Volume 661.53K
Target (mean) $37.17
Tgt Median $34.00
Tgt Low $20.00
Tgt High $68.00
# Analysts 12
Recom Strong_buy
Prev Close $13.41
Price $13.66
Change 1.86%
About

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$37.17
Mean price target
2. Current target
$13.66
Latest analyst target
3. DCF / Fair value
$37.17
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$13.66
Low
$20.00
High
$68.00
Mean
$37.17

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-07 main RBC Capital Outperform → Outperform $37
2026-03-09 main Citigroup Buy → Buy $35
2026-03-05 main HC Wainwright & Co. Buy → Buy $30
2026-03-04 main Chardan Capital Buy → Buy $29
2025-11-06 main RBC Capital Outperform → Outperform $39
2025-08-07 main Chardan Capital Buy → Buy $27
2025-08-06 main HC Wainwright & Co. Buy → Buy $23
2025-06-17 init RBC Capital — → Outperform $28
2025-05-29 reit HC Wainwright & Co. Buy → Buy $22
2025-05-16 main Mizuho Outperform → Outperform $26
2025-05-08 main Chardan Capital Buy → Buy $27
2025-03-06 main Chardan Capital Buy → Buy $33
2025-03-06 reit HC Wainwright & Co. Buy → Buy $22
2025-02-06 main Chardan Capital Buy → Buy $33
2025-01-07 init Citigroup — → Buy $33
2024-12-05 reit HC Wainwright & Co. Buy → Buy $22
2024-11-11 main Baird Outperform → Outperform $33
2024-11-11 main HC Wainwright & Co. Buy → Buy $22
2024-11-08 main Chardan Capital Buy → Buy $33
2024-10-29 main Chardan Capital Buy → Buy $28
News
RSS: Latest EYPT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-17 RIBEIRO RAMIRO Officer — 2,437 $15.00 $36,555
2026-04-17 RIBEIRO RAMIRO Officer — 2,437 $8.26 $20,130
2026-03-16 DUKER JAY S Chief Executive Officer — 1,500 $13.15 $19,724
2026-03-04 RIBEIRO RAMIRO Officer — 2,438 $17.87 $43,572
2026-03-04 RIBEIRO RAMIRO Officer — 2,438 $8.26 $20,138
2026-03-02 ELSTON GEORGE O Chief Financial Officer — 5,000 $0.00 $0
2026-02-17 RIBEIRO RAMIRO Officer — 2,437 $15.00 $36,555
2026-02-17 RIBEIRO RAMIRO Officer — 2,437 $8.26 $20,130
2026-01-06 ELSTON GEORGE O Chief Financial Officer — 15,285 — —
2026-01-06 LURKER NANCY S Director — 75,133 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
31.37
-27.50%
43.27
-5.97%
46.02
+11.14%
41.40
Operating Revenue
31.37
-27.50%
43.27
-5.97%
46.02
+11.14%
41.40
Cost Of Revenue
2.07
-44.34%
3.71
-19.86%
4.63
-44.37%
8.33
Reconciled Cost Of Revenue
2.07
-44.34%
3.71
-19.86%
4.63
-41.59%
7.93
Gross Profit
29.30
-25.92%
39.56
-4.41%
41.39
+25.12%
33.08
Operating Expense
272.74
+47.10%
185.41
+59.22%
116.45
+3.96%
112.02
Research And Development
221.04
+66.29%
132.93
+105.57%
64.66
+30.26%
49.64
Selling General And Administration
51.70
-1.50%
52.49
+1.35%
51.79
-14.15%
60.32
Selling And Marketing Expense
0.09
-31.30%
0.13
-98.88%
11.69
-54.17%
25.51
General And Administrative Expense
51.61
-1.43%
52.36
+30.56%
40.10
+15.18%
34.82
Other Gand A
51.61
-1.43%
52.36
+30.56%
40.10
+15.18%
34.82
Total Expenses
274.81
+45.30%
189.13
+56.19%
121.08
+0.62%
120.34
Operating Income
-243.43
-66.90%
-145.85
-94.30%
-75.07
+4.90%
-78.94
Total Operating Income As Reported
-243.43
-66.90%
-145.85
-94.30%
-75.07
+24.66%
-99.64
EBITDA
-229.34
-77.47%
-129.23
-87.28%
-69.00
+28.58%
-96.62
Normalized EBITDA
-229.34
-77.47%
-129.23
-91.01%
-67.65
+9.02%
-74.36
Reconciled Depreciation
2.31
+49.94%
1.54
+231.90%
0.46
-81.03%
2.45
EBIT
-231.65
-77.15%
-130.77
-88.25%
-69.47
+29.88%
-99.06
Total Unusual Items
0.00
0.00
+100.00%
-1.35
+93.95%
-22.26
Total Unusual Items Excluding Goodwill
0.00
0.00
+100.00%
-1.35
+93.95%
-22.26
Special Income Charges
0.00
0.00
+100.00%
-1.35
+93.95%
-22.26
Other Special Charges
—
—
1.35
-13.60%
1.56
Impairment Of Capital Assets
—
—
0.00
-100.00%
20.70
Net Income
-231.96
-77.25%
-130.87
-84.86%
-70.80
+30.77%
-102.25
Pretax Income
-231.68
-77.15%
-130.78
-84.95%
-70.71
+30.85%
-102.25
Net Non Operating Interest Income Expense
11.75
-22.04%
15.07
+164.36%
5.70
+638.94%
-1.06
Interest Expense Non Operating
0.03
+135.71%
0.01
-98.88%
1.25
-60.90%
3.19
Net Interest Income
11.75
-22.04%
15.07
+164.36%
5.70
+638.94%
-1.06
Interest Expense
0.03
+135.71%
0.01
-98.88%
1.25
-60.90%
3.19
Interest Income Non Operating
11.78
-21.90%
15.09
+117.12%
6.95
+226.09%
2.13
Interest Income
11.78
-21.90%
15.09
+117.12%
6.95
+226.09%
2.13
Other Income Expense
—
—
-1.35
+93.95%
-22.26
Tax Provision
0.28
+210.00%
0.09
+8.43%
0.08
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
+100.00%
-0.28
0.00
Net Income Including Noncontrolling Interests
-231.96
-77.25%
-130.87
-84.86%
-70.80
+30.77%
-102.25
Net Income From Continuing Operation Net Minority Interest
-231.96
-77.25%
-130.87
-84.86%
-70.80
+30.77%
-102.25
Net Income From Continuing And Discontinued Operation
-231.96
-77.25%
-130.87
-84.86%
-70.80
+30.77%
-102.25
Net Income Continuous Operations
-231.96
-77.25%
-130.87
-84.86%
-70.80
+30.77%
-102.25
Normalized Income
-231.96
-77.25%
-130.87
-87.68%
-69.73
+12.83%
-80.00
Net Income Common Stockholders
-231.96
-77.25%
-130.87
-84.86%
-70.80
+30.77%
-102.25
Diluted EPS
-3.17
-36.64%
-2.32
-27.47%
-1.82
+33.58%
-2.74
Basic EPS
-3.17
-36.64%
-2.32
-27.47%
-1.82
+33.58%
-2.74
Basic Average Shares
73.25
+30.11%
56.30
+44.71%
38.90
+4.25%
37.32
Diluted Average Shares
73.25
+30.11%
56.30
+44.71%
38.90
+4.25%
37.32
Diluted NI Availto Com Stockholders
-231.96
-77.25%
-130.87
-84.86%
-70.80
+30.77%
-102.25
Amortization
—
—
0.00
-100.00%
2.05
Amortization Of Intangibles Income Statement
—
—
0.00
-100.00%
2.05
Depreciation Amortization Depletion Income Statement
—
—
0.00
-100.00%
2.05
Depreciation And Amortization In Income Statement
—
—
0.00
-100.00%
2.05
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
364.00
-13.02%
418.46
+17.82%
355.18
+96.93%
180.36
Current Assets
328.65
-14.26%
383.31
+11.17%
344.80
+99.53%
172.81
Cash Cash Equivalents And Short Term Investments
306.09
-17.48%
370.91
+12.04%
331.05
+129.00%
144.56
Cash And Cash Equivalents
101.82
+2.12%
99.70
-64.55%
281.26
+194.11%
95.63
Other Short Term Investments
204.26
-24.68%
271.21
+444.74%
49.79
+1.76%
48.93
Receivables
0.65
+7.25%
0.61
-24.60%
0.81
-94.81%
15.50
Accounts Receivable
0.65
+7.25%
0.61
-24.60%
0.81
-94.81%
15.50
Inventory
1.81
-21.34%
2.31
-40.99%
3.91
+35.34%
2.89
Raw Materials
1.23
-25.83%
1.66
+27.17%
1.30
-7.59%
1.41
Work In Process
0.58
-9.88%
0.65
-26.53%
0.88
-18.18%
1.08
Finished Goods
—
0.00
-100.00%
1.72
+332.41%
0.40
Prepaid Assets
18.14
+124.63%
8.08
+0.57%
8.03
-11.52%
9.08
Other Current Assets
1.96
+39.79%
1.41
+39.25%
1.01
+29.03%
0.78
Total Non Current Assets
35.34
+0.52%
35.16
+238.59%
10.38
+37.57%
7.55
Net PPE
29.25
+0.24%
29.18
+185.10%
10.23
+38.33%
7.40
Gross PPE
35.26
+6.11%
33.23
+159.54%
12.80
+34.72%
9.51
Accumulated Depreciation
-6.02
-48.31%
-4.06
-57.80%
-2.57
-22.02%
-2.11
Properties
0.00
0.00
0.00
0.00
Construction In Progress
1.46
-3.12%
1.51
-59.58%
3.73
0.00
Other Properties
29.62
+7.33%
27.60
+242.04%
8.07
-5.04%
8.50
Leases
4.18
+1.26%
4.13
+309.52%
1.01
+0.00%
1.01
Goodwill And Other Intangible Assets
—
—
—
0.00
Other Intangible Assets
—
—
—
—
Other Non Current Assets
6.09
+1.89%
5.98
+3888.00%
0.15
+0.00%
0.15
Total Liabilities Net Minority Interest
57.88
-29.38%
81.96
-7.76%
88.86
+5.80%
83.99
Current Liabilities
37.02
-24.51%
49.05
-22.47%
63.26
+83.17%
34.54
Payables And Accrued Expenses
20.35
+13.09%
17.99
+57.93%
11.39
-10.73%
12.76
Payables
10.49
-10.50%
11.72
+80.21%
6.50
+9.88%
5.92
Accounts Payable
10.49
-10.50%
11.72
+80.21%
6.50
+9.88%
5.92
Current Accrued Expenses
9.86
+57.18%
6.27
+28.28%
4.89
-28.55%
6.84
Pensionand Other Post Retirement Benefit Plans Current
14.53
+22.86%
11.83
-6.34%
12.63
+32.75%
9.52
Current Debt And Capital Lease Obligation
—
—
—
10.47
Current Capital Lease Obligation
—
—
—
0.58
Current Deferred Liabilities
0.00
-100.00%
17.78
-53.92%
38.59
+3102.66%
1.21
Current Deferred Revenue
0.00
-100.00%
17.78
-53.92%
38.59
+3102.66%
1.21
Other Current Liabilities
2.14
+48.61%
1.44
+122.91%
0.65
+11.57%
0.58
Total Non Current Liabilities Net Minority Interest
20.86
-36.63%
32.92
+28.59%
25.60
-48.24%
49.45
Long Term Debt And Capital Lease Obligation
20.77
-4.97%
21.86
+345.54%
4.91
-86.10%
35.29
Long Term Debt
—
—
—
29.31
Long Term Capital Lease Obligation
20.77
-4.97%
21.86
+345.54%
4.91
-18.01%
5.98
Non Current Deferred Liabilities
0.00
-100.00%
10.85
-47.55%
20.69
+52.63%
13.56
Non Current Deferred Revenue
0.00
-100.00%
10.85
-47.55%
20.69
+52.63%
13.56
Other Non Current Liabilities
0.09
-57.56%
0.20
—
0.60
Stockholders Equity
306.11
-9.03%
336.50
+26.35%
266.32
+176.36%
96.37
Common Stock Equity
306.11
-9.03%
336.50
+26.35%
266.32
+176.36%
96.37
Capital Stock
0.08
+22.06%
0.07
+38.78%
0.05
+44.12%
0.03
Common Stock
0.08
+22.06%
0.07
+38.78%
0.05
+44.12%
0.03
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
82.83
+21.33%
68.27
+39.20%
49.04
+43.89%
34.08
Ordinary Shares Number
82.83
+21.33%
68.27
+39.20%
49.04
+43.89%
34.08
Additional Paid In Capital
1,410.05
+16.69%
1,208.42
+19.94%
1,007.56
+31.38%
766.90
Retained Earnings
-1,104.98
-26.57%
-873.02
-17.63%
-742.15
-10.55%
-671.35
Gains Losses Not Affecting Retained Earnings
0.96
-6.52%
1.03
+18.98%
0.86
+9.92%
0.79
Other Equity Adjustments
0.96
-6.52%
1.03
+18.98%
0.86
+9.92%
0.79
Total Equity Gross Minority Interest
306.11
-9.03%
336.50
+26.35%
266.32
+176.36%
96.37
Total Capitalization
306.11
-9.03%
336.50
+26.35%
266.32
+111.91%
125.68
Working Capital
291.63
-12.75%
334.26
+18.73%
281.54
+103.61%
138.27
Invested Capital
306.11
-9.03%
336.50
+26.35%
266.32
+95.61%
136.15
Total Debt
20.77
-4.97%
21.86
+345.54%
4.91
-89.28%
45.77
Capital Lease Obligations
20.77
-4.97%
21.86
+345.54%
4.91
-18.01%
5.98
Net Tangible Assets
306.11
-9.03%
336.50
+26.35%
266.32
+176.36%
96.37
Tangible Book Value
306.11
-9.03%
336.50
+26.35%
266.32
+176.36%
96.37
Line Of Credit
—
—
0.00
-100.00%
10.47
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-240.11
-90.22%
-126.23
-6832.05%
1.88
+102.88%
-65.00
Cash Flow From Continuing Operating Activities
-240.11
-90.22%
-126.23
-6832.05%
1.88
+102.88%
-65.00
Net Income From Continuing Operations
-231.96
-77.25%
-130.87
-84.86%
-70.80
+30.77%
-102.25
Depreciation Amortization Depletion
2.31
+49.94%
1.54
+231.90%
0.46
-81.03%
2.45
Depreciation
2.31
+49.94%
1.54
+231.90%
0.46
+17.17%
0.40
Amortization Cash Flow
—
—
0.00
-100.00%
2.05
Depreciation And Amortization
2.31
+49.94%
1.54
+231.90%
0.46
-81.03%
2.45
Amortization Of Intangibles
—
—
0.00
-100.00%
2.05
Other Non Cash Items
-4.83
+18.90%
-5.95
-595.44%
-0.86
-53.41%
-0.56
Stock Based Compensation
27.87
-24.13%
36.74
+204.72%
12.06
-14.95%
14.18
Provisionand Write Offof Assets
—
0.00
-100.00%
0.69
-64.44%
1.95
Asset Impairment Charge
—
—
0.00
-100.00%
20.70
Deferred Tax
0.28
+210.00%
0.09
+8.43%
0.08
0.00
Deferred Income Tax
0.28
+210.00%
0.09
+8.43%
0.08
0.00
Operating Gains Losses
—
—
1.35
-13.60%
1.56
Change In Working Capital
-33.78
-21.63%
-27.77
-147.17%
58.88
+2047.80%
-3.02
Change In Receivables
-10.67
-4271.72%
-0.24
-101.69%
14.43
+642.15%
-2.66
Changes In Account Receivables
-10.67
-4271.72%
-0.24
-101.69%
14.43
+642.15%
-2.66
Change In Inventory
0.49
-69.25%
1.60
+203.03%
-1.55
-104.34%
-0.76
Change In Payables And Accrued Expense
4.68
-18.39%
5.73
+277.29%
1.52
+26.79%
1.20
Change In Other Working Capital
-28.17
+2.96%
-29.03
-165.25%
44.48
+5667.46%
-0.80
Change In Other Current Assets
-0.11
+98.06%
-5.83
0.00
—
Investing Cash Flow
68.58
+131.26%
-219.35
-6517.04%
-3.31
+80.80%
-17.27
Cash Flow From Continuing Investing Activities
68.58
+131.26%
-219.35
-6517.04%
-3.31
+80.80%
-17.27
Net PPE Purchase And Sale
-3.12
+22.88%
-4.05
-16.34%
-3.48
-62.00%
-2.15
Purchase Of PPE
-3.28
+19.05%
-4.05
-16.34%
-3.48
-62.00%
-2.15
Sale Of PPE
0.15
0.00
—
—
Capital Expenditure
-3.28
+19.05%
-4.05
-16.34%
-3.48
-62.00%
-2.15
Net Investment Purchase And Sale
71.70
+133.30%
-215.30
-128256.55%
0.17
+101.11%
-15.12
Purchase Of Investment
-252.02
+36.73%
-398.30
-622.66%
-55.12
+60.38%
-139.12
Sale Of Investment
323.73
+76.90%
183.00
+231.02%
55.28
-55.42%
124.00
Financing Cash Flow
173.65
+5.87%
164.02
-12.32%
187.07
+27211.59%
-0.69
Cash Flow From Continuing Financing Activities
173.65
+5.87%
164.02
-12.32%
187.07
+27211.59%
-0.69
Net Issuance Payments Of Debt
-0.10
+0.00%
-0.10
+99.74%
-40.51
-2026.34%
2.10
Issuance Of Debt
—
0.00
-100.00%
5.30
-92.83%
73.88
Repayment Of Debt
-0.10
+0.00%
-0.10
+99.77%
-45.81
+36.17%
-71.77
Long Term Debt Issuance
—
0.00
-100.00%
5.30
-92.83%
73.88
Long Term Debt Payments
-0.10
+0.00%
-0.10
+99.77%
-45.81
+36.17%
-71.77
Net Long Term Debt Issuance
-0.10
+0.00%
-0.10
+99.74%
-40.51
-2026.34%
2.10
Short Term Debt Issuance
—
—
5.30
-87.92%
43.88
Short Term Debt Payments
—
—
-15.78
+52.77%
-33.40
Net Short Term Debt Issuance
—
—
-10.47
-200.00%
10.47
Net Common Stock Issuance
173.44
+6.20%
163.31
-27.79%
226.17
0.00
Proceeds From Stock Option Exercised
2.24
-62.68%
6.00
+77.58%
3.38
+754.94%
0.40
Net Other Financing Charges
-1.93
+62.75%
-5.18
-163.15%
-1.97
+38.21%
-3.19
Changes In Cash
2.12
+101.17%
-181.56
-197.81%
185.63
+323.76%
-82.96
Effect Of Exchange Rate Changes
—
—
—
—
Beginning Cash Position
99.85
-64.52%
281.41
+193.80%
95.78
-46.41%
178.74
End Cash Position
101.97
+2.12%
99.85
-64.52%
281.41
+193.80%
95.78
Free Cash Flow
-243.39
-86.82%
-130.28
-8001.87%
-1.61
+97.61%
-67.16
Interest Paid Supplemental Data
—
0.00
-100.00%
1.41
-45.96%
2.60
Income Tax Paid Supplemental Data
—
—
—
0.60
Common Stock Issuance
173.44
+6.20%
163.31
-27.79%
226.17
0.00
Issuance Of Capital Stock
173.44
+6.20%
163.31
-27.79%
226.17
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category